
AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth
AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC,










